ersonal use only
AnteoTech Ltd (ASX:ADO)
Company Presentation
10 March 2022
DISCLAIMER
Important Information
The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.
Forward-looking statements | ||
The presentation may contain certain "forward-looking statements". Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", | ||
"expect", "intend", "plan", "aim", "estimate", "target", "anticipate", "believe", "continue", "objectives", "outlook", "guidance" or other similar words, and include statements regarding AnteoTech's intent, | ||
onlybelief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward | ||
looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about | ||
future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective | ||
information. AnteoTech disclaims any obligation to update any forward looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements | ||
applicable to the Group. | ||
Not an offer of securities | ||
This presentation should not be relied on as a recommendation or forecast by AnteoTech Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell | ||
shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, | ||
usesituation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision | ||
EuGeni SARS-CoV-2 Ag RDT - CE Marked - not available in other jurisdictions | ||
ersonal | ||
• The COVID-19 rapid antigen test (RAT) must not be supplied for the purpose of self-testing | ||
• The COVID-19 RAT must only be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results | ||
• Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained) | ||
• Positive test results or symptomatic persons require immediate confirmatory testing with a polymerase chain reaction (PCR) test. | ||
10 March 2022 | 2 |
ANTEOTECH - TODAY
AnteoTech is commercialising innovative patented nano-technology - with lucrative revenue opportunities across two key growth sectors: Point of Care (POC) diagnostics and Lithium-ion(Li-io) battery market
ersonal use only
STRONG IP
POSITION
HIGH IMPACT
SECTORS
Unique, proprietary nano-polymer technology
- Proven product in market - AnteoBind
- Core technology has delivered proof of concept applications across Life Science & Energy applications
Developing solutions in rapid growth, high impact sectors
- Improving POC testing & assay development in diagnostics, drug development
- Improving Li-ion battery energy storage through enhanced silicon integration
GROWTH MARKETS
Active in growth markets
- POC diagnostics - Lateral Flow Assay (LFA) market forecast to grow to US$12.19b by 2027
- Lithium-ionbattery market - forecast to hit US$130 Billion by 2030.2
Ready to deliver - short to medium term opportunity
- Life Science - Growing distribution network and pipeline of tests.
- Li-ionbatteries - strong network of collaborators spanning battery value chain
10 March 2022
1. Source: Market Forecast:Lateral Flow Assay Market - Growth, Trends,COVID-19Impact, and Forecasts (2021 - 2027)Mordor Intelligence | |
2. Source: International Energy Agency World Energy Outlook 2021 | 3 |
CORPORATE SNAPSHOT
Headquartered in Brisbane, Australia
CORPORATE OVERVIEW: onlyASX code
Cash (as at 31 Dec 2021) Market Cap (at $0.18/per share) 52 week low - high ($/share)
Shares on issue
useDebt
Board and management holding (%)
Top 20 holding (%):
BOARD & MANAGEMENT :
Chairman ersonalChief Executive Officer
Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director
CFO and Company Secretary
10 March 2022
As at 4/03/2022
ADO $16.61m $397m
0.155 - 0.495
1,985,499,755 Nil
4.02%
28.63%
Dr Jack Hamilton
Derek Thomson
Dr Geoff Cumming
Glenda McLaughlin
Christopher Parker
Dr Katherine Woodthorpe AO
Tim Pritchard
SHARE PRICE & VOLUME (MARCH 2021 - MARCH 2022) | |||
0.5 | 40 | ||
0.45 | 35 | ||
0.4 | |||
30 | |||
0.35 | |||
$ 0.3 | 25 | ||
Millions | |||
0.25 | 20 | ||
0.2 | 15 | ||
0.15 | |||
10 | |||
0.1 | |||
0.05 | 5 | ||
0 | 0 | ||
Volume | Close | As at 4 March 2022 | |
4 |
POSITIONED FOR GROWTH
A strong internal capability and an expanding network of international distributors, partners and collaborators positions AnteoTech for growth.
ersonal use only
10 March 2022
Capability
Strong Scientific Team
- 18 Scientists across Energy
- Life Science
- 13 PhD's
- Quality & Compliance Team
- Clinical Study Manager
Collaboration
International Network
-
Scientific, manufacturing & industry
collaboration network spanning
whole battery value chain
Manufacturing
32 Million test capacity
- Spanish Manufacturing
- Australian Manufacturing
- mid 2022
- International expansion as
demand increases
Marketing & Sales
Customer Engagement Focus
- Senior marketing
executives (Australia/ Europe and India)
-
Sales & customer support
team in Brisbane - 2 PR firms
- Creative agency
Distribution
Growing Distribution Network
- 9 Distributors
- 17 Territories in Europe
and SE Asia
R&D Innovation
Ongoing Reader Development
-
Testing of new readers targeting new
segments.
IP Development
-
Securing IP through new
patent applications - 5 new provisional patent
applications filed in 2021 & 3 in 2022
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Anteotech Limited published this content on 10 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 March 2022 03:22:08 UTC.